Induction of antitumor immunity by semi-allogeneic and fully allogeneic electrofusion products of tumor cells and dendritic cells.
Immunization with the electrofusion product of tumor cells and dendritic cells (DCs) is a promising approach to cancer immunotherapy. Production of electrofusion vaccines currently requires the acquisition of tumor material and must be tailored to each individual. Alternative vaccine configurations were explored in this study. Results indicated that fusion vaccines with fully syngeneic, semi-allogeneic or fully allogeneic components, were all effective in inducing specific, long-lasting antitumor immunity. This previously undescribed activity of a fully allogeneic fusion product introduces the possibility of using defined allogeneic tumor and DC lines to simplify vaccine manufacturing.
Siders
William M
WM
Genzyme Corporation, 49 New York Avenue, Framingham, Massachusetts, USA.
Garron
Carrie
C
Shields
Jacqueline
J
Kaplan
Johanne M
JM
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology; D002459:Cell Fusion / Q000379:methods*; D045744:Cell Line, Tumor; D045142:Cross-Priming / Q000276:immunology; D016207:Cytokines / Q000378:metabolism; D003713:Dendritic Cells / Q000276:immunology*; D018274:Electroporation / Q000379:methods*; D005434:Flow Cytometry; D007109:Immunity / Q000276:immunology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology*; D014184:Transplantation, Homologous
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D016207:Cytokines